The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and substantial returns is undeniable, the linked risks are also significant. Many o